Allosteric regulation

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Retrieved on: 
星期三, 四月 3, 2024
Discovery, Epilepsy, GABAB, Senior, Glutamic acid, Dyskinesia, Glutamate (neurotransmitter), Drug discovery, Partnership, TBI, SIX, Chronic cough, NAM, CHF5, Therapy, DSM-IV codes, Janssen, Safety, ADX71149, Allosteric regulation, Janssen Pharmaceuticals, Dipraglurant, Research fellow, PAM, Pharmaceutical industry

With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.

Key Points: 
  • With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.
  • In return, Addex will receive CHF5 million and a 20% equity interest in Neurosterix.
  • “The launch of Neurosterix in partnership with Perceptive is an important validation of the Addex allosteric modulator drug discovery technology platform and provides the resources to accelerate development of important preclinical assets, including the M4 PAM and mGlu7 negative allosteric modulator (NAM) programs, into the clinic,” said Tim Dyer, CEO of Addex.
  • To guide the launch of Neurosterix, Tim Dyer, in addition to his role at Addex, will assume the role of CEO of Neurosterix.

Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders

Retrieved on: 
星期三, 四月 3, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Schizophrenia, Drug discovery, Patient, DSM-IV codes, Safety, Therapy, Allosteric regulation, Pharmaceutical industry

Neurosterix is leveraging decades of investment made by Addex in building a leading allosteric modulator discovery technology platform.

Key Points: 
  • Neurosterix is leveraging decades of investment made by Addex in building a leading allosteric modulator discovery technology platform.
  • The platform has a track record of identifying highly selective, brain penetrant small molecule drugs, a class that has the potential to revolutionize the treatment of neurological disorders.
  • Neurosterix’s lead program is a muscarinic acetylcholine receptor subtype 4 positive allosteric modulator (“M4 PAM”) for the treatment of patients suffering from schizophrenia.
  • However, Neurosterix will accelerate its pursuit of these exciting medicines through acquiring Addex’s industry-leading proprietary high-throughput allosteric modulator drug discovery platform and a portfolio of preclinical neuroscience assets.

Alumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS

Retrieved on: 
星期五, 三月 1, 2024
Central nervous system, Research, EAE, Treatment, Rat, Multiple sclerosis, Allosteric regulation, CNS, Microdialysis, Patient, TYK2, Poster, Brain, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Alumis Inc., a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced preclinical data for A-005 at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) forum. A-005 is a potential first-in-class, brain penetrant tyrosine kinase 2 (TYK2) inhibitor being developed for the treatment of multiple sclerosis (MS), Parkinson’s Disease and other neuroinflammatory and neurodegenerative diseases, with Phase I clinical trial initiation planned in the first half of 2024.

Key Points: 
  • “Therapeutic inhibition of TYK2 has been clinically validated to treat immune-mediated diseases, but there remains a medical need for the clinical development of an allosteric TYK2 inhibitor targeting the central nervous system,” said David Goldstein, Ph.D., Chief Scientific Officer, Alumis.
  • Presented as a poster, results demonstrated A-005 to be highly potent and inhibit TYK2 pathway activation in human whole blood, PBMCs and microglial cells.
  • The data also underscored the ability of A-005 to reduce EAE clinical scores when administered prophylactically or therapeutically.
  • Data are being presented during ACTRIMS 2024 Poster Session 2 on March 1, 2024, from 6:00-7:30 pm ET, Poster Number 400.

Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Retrieved on: 
星期四, 二月 22, 2024
Breast cancer, BID, Genentech, Research, Fulvestrant, Investment, HR, Discovery, Allosteric regulation, Completeness, Therapy, Patient, Clinical trial, Pharmaceutical industry

CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported fourth quarter and full year 2023 financial results and corporate highlights.

Key Points: 
  • “We are very pleased with the RLY-2608 data disclosed to-date and how its clinical profile continued to mature throughout last year.
  • Revenue: There was no material revenue for the fourth quarter of 2023 or 2022.
  • Revenue was $25.5 million for the full year 2023, as compared to $1.4 million for the full year 2022.
  • G&A Expenses: General and administrative expenses were $16.8 million for the fourth quarter of 2023, as compared to $16.4 million for the fourth quarter of 2022.

Addex to Present at Biotech Showcase™ 2024

Retrieved on: 
星期五, 一月 5, 2024
Glutamic acid, Protein, Drug discovery, DSM-IV codes, PAM, Janssen Pharmaceuticals, Biotechnology, Epilepsy, Depression, NAM, ADX71149, Allosteric regulation, SIX Swiss Exchange, Psychosis, Glutamate (neurotransmitter), Therapy, GABAB, Schizophrenia, Chronic cough, American depositary receipt

For more information or to schedule a one-on-one meeting, please submit a request via the Biotech Showcase partnering platform or by sending an email to [email protected] .

Key Points: 
  • For more information or to schedule a one-on-one meeting, please submit a request via the Biotech Showcase partnering platform or by sending an email to [email protected] .
  • Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders.
  • Addex’s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates, with a focus on substance use disorder.

Latest Updates of 7 Viva's Portfolio Companies

Retrieved on: 
星期五, 七月 28, 2023
Dai, FALCON, Head, Acquisition, Patient, Fabry disease, SUA, Tissue, Pharma, Gout, Therapy, Heart failure, CSO, GABAA receptor negative allosteric modulator, Research, NAM, VBI, Small RNA, Medicine, Liver, Growth, CIO, Listeria monocytogenes non-coding RNA, Phase, FDA, URAT1, G protein-coupled receptor, SRT, PAR2, DSM-IV codes, Gq alpha subunit, Glaucoma, Ocular hypertension, SAN, Mercury (element), Allosteric regulation, IOP, Flare, Central nervous system, Drug development, Quality of life, Facet joint arthrosis, RNA, Novartis, Cardiology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Fine chemical, Riparian zone, Domain, Pfizer

WATERTOWN, Mass.-- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases. Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.

Key Points: 
  • WATERTOWN, Mass.-- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases.
  • Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.
  • In exchange for exclusive rights to a Riparian preclinical program, Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics.
  • DTx Pharma utilizes its groundbreaking FALCON™ platform, a conjugated oligonucleotide technology using fatty acid ligands, to tackle the delivery challenges of oligonucleotide therapies.

Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities

Retrieved on: 
星期一, 六月 5, 2023
Allosteric regulation, Failure, G protein-coupled receptor, CHUM, Centre hospitalier, Cancer, PAR2, GABAA receptor negative allosteric modulator, Research, CAF, NAM, Immunotherapy, Fibrosis, GPCR, Patient, Neoplasm, EP4, Therapy, Immunosuppression, Gq alpha subunit, Pharmaceutical industry, Vaccine

Through this precision research strategy, backed by two decades of deep-expertise in understanding GPCRs, the Company has developed a novel series of potent and selective PAR2 NAMs.

Key Points: 
  • Through this precision research strategy, backed by two decades of deep-expertise in understanding GPCRs, the Company has developed a novel series of potent and selective PAR2 NAMs.
  • PAR2 is a novel therapeutic target in oncology and immuno-oncology, involved in several processes such as tumor proliferation, resistance to immunotherapy and fibrosis.
  • Domain nominated DT-9045 as a first-in-class PAR2 NAM clinical candidate based on its added-value, unique properties and greater therapeutic potential in comparison to biologics targeting PAR2 currently in the clinic by several competitors.
  • Dr. Pascal Neuville, CEO of Domain Therapeutics, commented: “The nomination of our first-in-class PAR2 NAM drug candidate, DT-9045, is an exciting step forward for Domain Therapeutics and for cancer treatment in general.

Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease

Retrieved on: 
星期三, 五月 3, 2023
Neuron, GBA1, Biotechnology, Survival, Pathology, Innovation Agency (Azerbaijan), Research, Dementia, Trial of the century, Science, Allosteric regulation, Patient, Lysosome, Glucocerebrosidase, Therapy, CHF, Pharmacology, Disease, Pharmaceutical industry

BETHESDA, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Innosuisse, the Swiss Innovation Agency, supports GT Gain Therapeutics SA with the amount of CHF 2.5 million (~$2.8 million) to develop GT-02287, Gain’s lead program for GBA1 Parkinson’s disease.

Key Points: 
  • BETHESDA, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Innosuisse, the Swiss Innovation Agency, supports GT Gain Therapeutics SA with the amount of CHF 2.5 million (~$2.8 million) to develop GT-02287, Gain’s lead program for GBA1 Parkinson’s disease.
  • GBA1 mutations are the major genetic risk factor for Parkinson’s disease and are associated with earlier onset of the disease, faster disease progression and increased rates of cognitive decline.
  • These findings support the potential of GT-02287 to slow or halt disease progression in GBA1 Parkinson’s disease.
  • Support per project amounts to a maximum of CHF 2.5 million and covers up to 70 per cent of project costs.

PIC Therapeutics Presents Pre-Clinical Data Update on eIF4E Regulators at AACR Annual Meeting 2023

Retrieved on: 
星期一, 四月 17, 2023
Oncology, Health, Stem Cells, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, DNA, AACR, Cell death, Aggression, Neoplasm, Cell, Survival, American Association for Cancer Research, CDK, Messenger, Concentration ratio, Patient, Apoptosis, Allosteric regulation, PIC, Poster, Therapy, Factorization of polynomials, Metastasis, ER, Breast cancer, DNA repair, Pharmaceutical industry, Vaccine

PIC compound regulation of eIF4E induces rapid commitment to apoptosis and selective proteomic shifts that are consistent with canonical eIF4E regulation including cell cycle impacts, e.g.

Key Points: 
  • PIC compound regulation of eIF4E induces rapid commitment to apoptosis and selective proteomic shifts that are consistent with canonical eIF4E regulation including cell cycle impacts, e.g.
  • Previous communications revealed our eIF4E regulators potently cause cell death in primary breast cancer organoid models, but spared models derived from healthy tissue.
  • Our eIF4E regulators did not impair survival of these cells up to a maximum tested dose of 25 micromolar.
  • Our eIF4E regulators represent a potential beneficial therapeutic approach to address multiple resistant cancer patient populations and fulfill the promise of this elusive target.

Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology

Retrieved on: 
星期一, 三月 27, 2023
TKI, Allosteric regulation, MDM2, Employment, Novartis Institute for Tropical Diseases, Obesity, Biomedical Research, Therapy, NASH, NIBR, CML, Cancer, Research, Acute leukemia, Histone deacetylase inhibitor, University of Texas Southwestern Medical Center, Novartis, Memorial Sloan Kettering Cancer Center, Fatty liver disease, Weill Cornell Medicine, Mount Athos, Pharmaceutical industry, Nursing, Neuroscience, New York University, Tern

as chief medical officer of Terns oncology, effective May 1, 2023.

Key Points: 
  • as chief medical officer of Terns oncology, effective May 1, 2023.
  • Dr. Kuriakose brings more than a decade of clinical development and medical affairs experience spanning early through late phase development in several oncology indications at Novartis and Calithera Biosciences, where he most recently was serving as chief medical officer.
  • After Dr. Kuriakose commences his employment at Terns, Kerry Russell, M.D., will assume the role of chief medical officer of Terns metabolic with responsibility for Terns’ NASH and obesity programs.
  • I look forward to leveraging my experience to advance TERN-701 for the treatment of CML and expand Terns’ oncology franchise,” commented Dr. Kuriakose.